United States Patent 10,548,903: A Method Claiming Acolbifene Plus DHEA to Prevent/Reduce Male Androgen Deficiency
What does US 10,548,903 claim, at the claim-logic level?
US 10,548,903 claims a method of reducing the incidence of male androgen deficiency symptoms or diseases in an aging male patient, with a specific drug pairing and specific patient selection thresholds, plus a large downstream symptom/disease rubric.
Core independent claim (Claim 1) structure
Claim 1 is built as a sequence of requirements:
-
Patient and intent
- “an aging male patient in need of said prevention”
- patient selection includes “non-symptomatic patients initially selected to undergo said method”
-
Functional endocrine condition
- “wherein said aging male patient has functional adrenals and testis”
-
Two-drug combination, both “therapeutically effective”
- (i) dehydroepiandrosterone (DHEA) or a sex steroid precursor/prodrug thereof
- (ii) acolbifene (or a selective estrogen receptor modulator (SERM) or prodrug thereof)
- The SERM “stimulates LH secretion which increases the level of circulating testosterone”
-
Acolbifene stereochemical constraint
- “selective estrogen receptor modulator is acolbifene”
- “optically active compound having an absolute configuration S on carbon 2”
-
Explicit baseline biochemical selection thresholds
- “values of serum testosterone below 3.0 ng/mL and/or values of serum dehydroepiandrosterone below 2.0 ng/mL”
-
Clinical scope of the outcome
- “reducing the incidence of male androgen deficiency symptoms or diseases”
- Dependent claim 39 tightens the association to “male hypogonadism.”
Dependent claims 2-38: outcome coverage expansion by enumeration
Claim 2 defines symptoms/diseases from a broad list that includes:
- sexual and neuropsychiatric: loss of libido, erectile dysfunction, depression, memory loss, cognition loss, Alzheimer’s disease, dementia, insomnia, decreased sense of well-being
- musculoskeletal/body composition: tiredness, loss of energy, bone loss, muscle loss, muscle weakness, fat accumulation
- metabolic/cardiovascular: obesity, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease, type 2 diabetes
- endocrine-on-target/off-target: gynecomastia (and also explicitly addresses breast cancer risk in Claim 4)
Claims 3 and 4 add risk-management and tissue-selectivity framing:
- Claim 3: “no estrogenic activity in breast, uterine or endometrial tissues”
- Claim 4: “reduces the risk of the male patients acquiring breast cancer”
Claims 5-8 define combination and administration route:
- Claim 5: combination therapy can include human chorionic gonadotropin (hCG)
- Claims 6-8: SERM and/or DHEA can be administered rectally, orally, or percutaneously
Claims 9-38 function as symptom-specific dependent claims, matching elements of Claim 2 but with narrower disease assignment.
What Claim 1 is really doing legally
Claim 1 is not a generic “testosterone restoration” claim. It is a prevention/intervention method with (a) patient endocrine status, (b) baseline serum thresholds, and (c) a defined pharmacologic mechanism pair:
- DHEA as a steroid precursor route
- acolbifene as a SERM route via LH stimulation leading to increased circulating testosterone
How narrow is the claim, and what breaks it?
From a patent-landscape attack perspective, Claim 1 is narrow in some dimensions and broad in others.
Narrow elements (high “breakability”)
A defendant can potentially design around if any of the following elements is removed or materially altered:
- Acolbifene identity: Claim 1 requires “selective estrogen receptor modulator is acolbifene” with stereochemical definition. A different SERM may not meet literal wording.
- Mechanism linkage: the SERM must “stimulate LH secretion which increases the level of circulating testosterone.”
- Baseline biomarkers and thresholds:
- testosterone < 3.0 ng/mL and/or DHEA < 2.0 ng/mL
- Patient endocrine status: “functional adrenals and testis”
- Intended population: “non-symptomatic patients initially selected” for prevention
Broad elements (low “breakability”)
Once the core pairing and patient logic are met, the outcome list is extremely broad:
- covers many androgen deficiency symptom domains
- includes dementia/Alzheimer’s, which are high-risk broadening targets for obviousness and enablement challenges in many landscapes
The administration route is flexible (rectal, oral, percutaneous) and combination therapy can include hCG.
What is the claim’s practical scope: method claims and “incidence reduction”?
The claim’s phrasing is “reducing the incidence” and “prevention” of male androgen deficiency symptoms/diseases. That tends to matter in enforcement because it ties method infringement to:
- patient selection criteria (non-symptomatic baseline biochemical thresholds)
- the administration of the stated combination
- a clinical intent/outcome framed as incidence reduction
In practice, that can be enforced if the accused protocol screens asymptomatic men with the specified thresholds and administers the combination.
How strong are the enforceability risks: clarity, enablement, and written description (landscape-style)?
Even without litigated record here, the claim’s structure creates several common validity vectors for challengers:
1) Broad outcome enumeration vs. single mechanistic combination
Claim 2 enumerates conditions that span:
- sexual function
- metabolic syndrome and cardiovascular risk
- neurocognitive disorders like Alzheimer’s disease and dementia
A challenger can argue overbreadth: the claim ties these diverse outcomes to the same dosing concept, but the independent claim does not include mechanistic markers or evidence-linked surrogates for each condition. In method claims, broad outcome lists can increase vulnerability if support in the specification is thin relative to the breadth.
2) Testosterone and DHEA threshold specificity can cut both ways
Thresholds (<3.0 ng/mL testosterone; <2.0 ng/mL DHEA) can help definiteness and reduce ambiguity, but they also introduce a question of:
- how the specification supports these cutoffs as “therapeutically effective” selection criteria across populations
- whether alternative lab methods/assays impact compliance with literal thresholds
3) SERM “no estrogenic activity” as a blanket tissue statement
Claim 3 requires “no estrogenic activity in breast, uterine or endometrial tissues.” Such statements often raise:
- enablement/written description scrutiny if they rest on limited preclinical models
- “no estrogenic activity” as an absolute can be argued as overbroad depending on data
What is likely missing for a tight “prevention” claim?
The claim requires:
- non-symptomatic selection
- prevention of incidence
But the dependent claims do not specify:
- treatment duration
- stopping rules
- follow-up endpoints
- dose ranges (not provided in the excerpt)
In many method patents, the lack of dosing and protocol parameters can cut enforceability for specific accused regimens but can also invite validity attacks if the specification does not sufficiently teach how to carry out “prevention” with predictable outcomes.
How does hCG fit: does Claim 5 expand or dilute infringement?
Claim 5 allows combination therapy with hCG. Legally:
- adding hCG does not remove infringement risk because Claim 5 is dependent on Claim 1
- it can matter for enforcement strategy because many real-world hypogonadism regimens include hCG, and the claim anticipates that combination
A competitor that uses acolbifene + DHEA alone could still infringe Claim 1; a competitor using acolbifene + DHEA + hCG could infringe Claim 5 as well if other elements are met.
Route-of-administration claims: do they broaden liability?
Claims 6-8 expand possible infringement vectors across:
- rectal administration
- oral administration
- percutaneous administration
Because Claim 1 does not restrict route, these dependent claims primarily clarify that accused protocols using different dosage forms can map into the claim family.
What does the patent landscape likely look like around this claim theme?
US 10,548,903 sits at the intersection of:
- androgen deficiency prevention/therapy strategies
- DHEA use as a steroid precursor approach
- SERM-driven LH stimulation for endogenous testosterone elevation
- acount of breast cancer risk mitigation for male patients
- management of androgen deficiency symptom domains, including metabolic/cardiovascular and neurocognitive labels
In landscape terms, this creates three competitor clusters:
-
Alternative SERM-LH strategies
- other SERMs that stimulate LH/testosterone could be outside literal scope if not “acolbifene”
- but they may still face doctrine-of-equivalents pressure depending on how strictly “acolbifene” is tied to functional constraints and stereochemistry
-
Alternative steroid precursors or androgen restoration
- replacing DHEA with another precursor or prodrug can avoid literal Claim 1 if it is not “dehydroepiandrosterone”
- but the claim’s phrasing “sex steroid precursor” and “prodrug thereof” can create an ambiguity space for challengers and litigants depending on how “dehydroepiandrosterone” is construed in the full patent text (not shown in the excerpt)
-
Metabolic and neurocognitive disease management using testosterone-adjacent therapies
- if accused products are positioned for Alzheimer’s/dementia or cardiovascular outcomes, the claim’s enumeration could be used aggressively in enforcement narratives, even though the mechanism is shared
Where is the claim most vulnerable in a patentability challenge?
Based on the claim content alone, the primary vulnerability points for a third-party challenge would be:
- Overbreadth of indications relative to a single combination mechanism (DHEA + acolbifene)
- Absolute “no estrogenic activity” language in Claim 3 if the supporting data is not comprehensive across tissues and endpoints
- Prevention/incidence reduction framing without protocol specificity (dose, schedule, treatment duration)
- Precision of baseline thresholds may or may not be grounded by robust disclosure as a selection strategy for prevention in non-symptomatic men
Key patent-landscape questions for investors and R&D
-
Does any major competitor plan protocols that match the full selection logic?
- non-symptomatic men
- testosterone <3.0 ng/mL and/or DHEA <2.0 ng/mL
- functional adrenals and testis
- combination of DHEA with acolbifene
-
Is the competitive differentiator a different SERM or different precursor?
- If yes, literal infringement risk decreases sharply because Claim 1 fixes acolbifene and DHEA explicitly.
- If they mimic the combination but substitute components, the fight shifts to equivalence and claim construction.
-
Do competitors target the same outcome enumerations?
- Even if they avoid literal thresholds, marketing and clinical trial endpoints could create argument hooks for mapping to the claim’s symptom/disease list.
-
Is the “breast cancer risk reduction” strategy used as part of clinical positioning?
- Claim 4 hard-codes breast cancer risk reduction.
- If competitors position similarly while using different SERMs or different endocrine elevation logic, their avoidance may depend on claim construction and evidence of tissue selectivity.
Claim-to-risk map: what an accused protocol must do to infringe
| Accused protocol element |
Must match Claim 1 literally? |
Practical risk implication |
| Aging male patient in need of prevention |
Yes |
Lowers infringement if accused targets symptomatic men only |
| Non-symptomatic initial selection |
Yes |
Screening criteria become central |
| Functional adrenals and testis |
Yes |
Biologic status must fit |
| DHEA (or claimed precursor/prodrug) |
Yes |
Substitution can reduce risk |
| Acolbifene (S stereochemistry at carbon 2) |
Yes |
Substitution with another SERM can avoid literal mapping |
| SERM increases testosterone via LH stimulation |
Likely yes |
A different mechanism can reduce mapping |
| Baseline testosterone < 3.0 ng/mL and/or DHEA < 2.0 ng/mL |
Yes |
Laboratory/threshold protocol drives enforcement posture |
| Outcome: prevention/incidence reduction of listed symptoms/diseases |
Yes |
Clinical endpoints and labeling matter |
Key Takeaways
- US 10,548,903 is a method-prevention claim anchored on patient selection (non-symptomatic, functional adrenals and testis, specific testosterone/DHEA thresholds) and a two-drug combination: DHEA + acolbifene with an S stereochemical constraint.
- The claim’s outcome scope is extremely broad via dependent claim enumeration, spanning sexual dysfunction, metabolic/cardiovascular disease, and neurocognitive disorders.
- The claim adds tissue-selectivity/risk management hooks: “no estrogenic activity” and breast cancer risk reduction, plus flexible administration routes.
- In landscape terms, design-around strategy most likely hinges on substituting either the SERM (acolbifene) or the precursor (DHEA) and/or avoiding the specific baseline screening thresholds and non-symptomatic prevention framing.
FAQs
-
Is the independent claim limited to oral dosing?
No. Dependent claims add rectal, oral, and percutaneous administration options while Claim 1 itself does not restrict route.
-
Does the claim require both DHEA and acolbifene?
Yes. Claim 1 requires administration of DHEA (sex steroid precursor) in association with an SERM specified as acolbifene.
-
What patient criteria make infringement enforcement more feasible?
The claim requires non-symptomatic men with functional adrenals and testis and baseline serum levels testosterone < 3.0 ng/mL and/or DHEA < 2.0 ng/mL.
-
Does the claim cover Alzheimer’s disease and dementia?
Yes. Claim 2 includes “Alzheimer’s disease” and “dementia” in the list of symptoms or diseases.
-
Does the patent address breast cancer risk in men?
Yes. Claim 4 claims that the method reduces the risk of male patients acquiring breast cancer, and Claim 3 recites lack of estrogenic activity in breast, uterine, and endometrial tissues.
References
[1] United States Patent US 10,548,903.
